DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
K••• O•••••••• I••
Drug Discovery & Developmentgroup grade Aon a schedule nowsponsor not established · possible relationship
Also written as: 16; 2023; 6; 6/16/2023; Equity; Inc. and
Principal held
at least $5.5M
sum of BDC pieces, a lower bound
Fair value
$6.4M
102c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
2 equity pieces beside them
Next maturity
Nov 1, 2027
$5.5M inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2026
Events
2
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $5.5M | 102c | S+240 bp | Nov 1, 2027 | 1 |
Lenders
every BDC piece at the latest quarter end, largest principal first
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, N••••••• 2027, P•••• + 2.40%, F•••• rate 8.65%, 6.05% E••• Fee | $5.5M | $5.8M 102c | S+240 bp |
| H••••••• C••••••• I••• | equity equity C••••• S•••• | Not disclosed | $525,000 95c | |
| H••••••• C••••••• I••• | warrants equity W••••••, 11/2/2022, C••••• S•••• | Not disclosed | $19,000 22c |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $5.5M | $5.8M | 102c | 0 |
| Mar 31, 2026 | 1 | $5.5M | $5.8M | 101c | 0 |
| Dec 31, 2025 | 1 | $11.0M | $11.7M | 102c | 0 |
| Sep 30, 2025 | 1 | $5.5M | $5.8M | 102c | 0 |
All 15 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 1 | $5.5M | $5.8M | 102c | 0 |
| Mar 31, 2025 | 1 | $5.5M | $5.7M | 101c | 0 |
| Dec 31, 2024 | 1 | $5.5M | $5.7M | 102c | 0 |
| Sep 30, 2024 | 1 | $5.5M | $5.7M | 102c | 0 |
| Jun 30, 2024 | 1 | $5.5M | $5.7M | 102c | 0 |
| Mar 31, 2024 | 1 | $5.5M | $5.8M | 104c | 0 |
| Dec 31, 2023 | 1 | $11.0M | $11.5M | 104c | 0 |
| Sep 30, 2023 | 1 | $5.5M | $5.7M | 103c | 0 |
| Jun 30, 2023 | 1 | $5.5M | $5.6M | 102c | 0 |
| Mar 31, 2023 | 1 | $5.5M | $5.5M | 100c | 0 |
| Dec 31, 2022 | 1 | $5.5M | $5.4M | 100c | 0 |
What changed
- Maturity approachingNov 1, 2027
- Maturity approachingNov 1, 2027
Sponsor
Possible relationship, not established: A•••• C•••••• A••••••• L••, because a company of this name is on the sponsor's portfolio page (confidence 0.7). No deal announcement or filing names it as a party, so it is not shown as this borrower’s sponsor.
- A•••• C•••••• A••••••• L••
- the sponsor's own portfolio page lists a company of this nameestimatedavorocapital.com"••• Locked"
Identity
- Group key
- K••• O•••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it